EIKN

Eikon Therapeutics, Inc.

BS score 43.6LOWPHASE2 · mkt cap $487.8M · rev ttm $0

drug hypothesis

IMP1734 modulates PARP1 to treat Advanced Solid Tumors.

moa:PARP1 selective inhibition - blocks poly(ADP-ribose) polymerase 1 enzyme involved in DNA repair, potentially causing synthetic lethality in tumors with DNA repair deficiencies.

score breakdown

trial design70

base rate disconnect29

language red flags20

composite43.6

valuation analysis

market cap$487.8M

revenue ttm$0

phasePHASE2

historical base rate10%

disconnect ratio1.0x

lead trialNCT06253130

meta

cik0001861123

first discovered2026-04-09

last updated2026-04-10

statusACTIVE

llm model—

extracted at2026-04-10

trial design

Phase 1, first-in-human, non-randomized, non-placebo controlled study in participants with advanced solid tumors. Enrollment target: 156 subjects. Start date: 2023-12-11, Primary completion: 2027-06-01.

primary endpoint:Number of subjects with adverse events, treatment emergent adverse events or serious adverse events (Consent to 30 + 7 days post last dose of IMP1734)

claimed differentiation

NOT STATED - No differentiation claims provided in available filing data

language red flags

INSUFFICIENT DATA - SEC filing business section appears incomplete (only contains '5'), no company statements, risk disclosures, or forward-looking language available for analysis